These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Kim H; Ha SY; Kim J; Kang M; Lee J Curr Oncol; 2020 Aug; 27(4):e436-e439. PubMed ID: 32905211 [TBL] [Abstract][Full Text] [Related]
5. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Gaffuri P; Espeli V; Fulciniti F; Paone G; Bergmann M Pathologica; 2019 Sep; 111(3):92-97. PubMed ID: 31748755 [TBL] [Abstract][Full Text] [Related]
6. Safety of pembrolizumab for the treatment of melanoma. Martin-Liberal J; Kordbacheh T; Larkin J Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979 [TBL] [Abstract][Full Text] [Related]
7. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. Nardin C; Borot S; Beaudoin MA; Cattin F; Puzenat E; Gauthier AS; Schillo F; Borg C; Aubin F Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624 [TBL] [Abstract][Full Text] [Related]
8. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma. Hanna KS Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999 [TBL] [Abstract][Full Text] [Related]
9. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. Woodbeck R; Metelitsa AI; Naert KA Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748 [TBL] [Abstract][Full Text] [Related]
10. Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab - Differences and Similarities in Comparison to "endogenous" autoimmune Type A Gastritis and a review of literature. Ecker ME; Weckauf H; Tebbe S; Schuppert F Z Gastroenterol; 2023 Oct; 61(10):1385-1393. PubMed ID: 36963423 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430 [TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. Yatim N; Mateus C; Charles P Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma. Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma. O'Connor C; Finnegan P; Power DG; Bennett M; Bourke JF Immunotherapy; 2022 Sep; 14(13):1021-1026. PubMed ID: 35892257 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report. Jabkowski J; Loidl A; Auinger B; Kehrer H; Sepp N; Pichler R Front Immunol; 2021; 12():606056. PubMed ID: 34220792 [TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature. Lei H; Sun W; Liu X; Wang C J Gastrointest Cancer; 2024 Sep; 55(3):1-8. PubMed ID: 38787493 [TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. Roncati L Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741 [TBL] [Abstract][Full Text] [Related]
20. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. Shao K; McGettigan S; Elenitsas R; Chu EY J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]